BRAF and metastatic melanoma: Researchers have found in clinical studies that the use of BRAF inhibitors in combination with MEK inhibitors in patients with metastatic melanoma can reduce the development of resistance to BRAF inhibitors in patients, thereby enhancing the therapeutic effect (176).